Cap Innov'Est 2

VistaCare is an innovative French VSE specializing in medical devices. They develop, manufacture, and distribute medical devices for the treatment of the critical phase of acute and chronic wounds. The company's technology enhances the quality of life and the care pathway for patients with wounds, as well as simplifying the daily lives of caregivers by drastically lowering treatment times and hospital stays.

Opencell was created in 2015 to leverage an open source telco billing project initiated in 2007 by David Meyer, their current CEO. Their mission is to provide the first agile monetization platform capable of filling the gap between costly and complex legacy billing solutions and the overly simplistic “one size fits all” SaaS solutions that cover only the most basic requirements. Opencell is now the open source monetization and billing platform with over 40 successful implementations in multiple industries and countries.

Defymed is a worldwide leader in the development of innovative implantable medical devices that change the paradigm of therapeutics' administration. Defymed's innovations were developed to limit adverse events related to current standard of care based on site specific delivery of therapeutics. Our solutions aim for a precise administration of drugs, in a physiologic site, in order to improve disease's management and patients' quality of life. Up to date, two first in class technologies were developed by Defymed: MailPan®, a physiologic cell encapsulation device, and ExOlin®, a targeted drug delivery device (in clinics). Defymed owns an exclusive technology and know-how which positions its medical devices as a platform to meet several therapeutic applications, among which type 1 diabetes, hemophilia and cancer management. Defymed is certified ISO13485:2016. Defymed relies also on a strong and unique worldwide network gathering experts from the cell therapy and drug delivery fields. Defymed has been rewarded several times in Europe and in the USA, for its unique approaches to reinvent patients' journey.

Syndivia is a biotechnology company. Syndivia's vision is to deliver the best treatment to cancer patients by harnessing unique properties of tumour hallmarks and microenvironment.

Urania Therapeutics company is developing a unique SBDD platform for the generation of new readthrough compounds with high potential in cancer and monogenic disorders.

Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies. Exeliom develops a new class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system. The company was founded in 2016 and is headquartered in Dijon, France.

Medsenic is a privately held company that manufactures drugs for the treatment of autoimmune diseases.

Opencell was created in 2015 to leverage an open source telco billing project initiated in 2007 by David Meyer, their current CEO. Their mission is to provide the first agile monetization platform capable of filling the gap between costly and complex legacy billing solutions and the overly simplistic “one size fits all” SaaS solutions that cover only the most basic requirements. Opencell is now the open source monetization and billing platform with over 40 successful implementations in multiple industries and countries.

Inoviem Scientific is a privately-owned contract research biotech (CRB) offering preclinical and clinical services that use cutting-edge proprietary technologies to speed up drug-development. Our pioneering technologies allow us to work in any therapeutic field and with any therapeutic compound (small chemical molecules, fragments, proteins, peptides, antibodies, etc). Our clients are any laboratories in the private or academic sphere working to develop therapeutic compounds. Our innovatory force lies with the technologies we have developed, and our strength generally resides in our ability to analyse drug-target interaction to a high degree of precision directly on crude human tissue, thus respecting physiological conditions. Our goal is to be your partner of choice for the development of drug candidates. Our technologies have the potential to bring to light information hidden within crude human tissue obtained from patients or healthy donors. Their use will significantly improve your chances of marketing your drug. As a technollogy and innovation driven CRB, Inoviem Scientific is continuously investing human and financial resources in the development of complementary technologies to bring the best technological, creative and innovative solutions to its clients. This continuous investment will reinforce our analysis power driving Inoviem Scientific to become: From preclinical to clinical: A leading explorer of drug-target interaction!

PeptiMimesis is a strategic partner in the design, the discovery and the early development of transmembrane therapeutic peptides. Our innovative approach enables the identification of peptidomimetic candidates interfering with the hetero- and/or the homodimerization of target receptors. PeptiMimesis will develop its pipeline against key targets in the fields of oncology, immuno-oncology and immune disease and is open to initiate collaboration with pharma partners on receptors of interest.

Fibermetrix propose innovative solutions for real-time radiations dose monitoring within the medical and industrial fields. Its sensors, providing automatic feedback of patient or occupationnal dose to increase radiation awareness, are based on optical fiber patented technology*. Thanks to its skills in radiation detection, dosimetry and in innovative sensors manufacturing, Fibermetrix's staff develops full integrated or handheld sensors with variable geometry providing punctual or multichannel acquisition and remote measuring.

Wizzvet is the first interactive platform for veterinary telemedicine in the form of a professional social network. WIZZVET offers a huge and up-to-date range of web conferences with two to three new online courses each week granting you continuing education points.

PeptiMimesis is a strategic partner in the design, the discovery and the early development of transmembrane therapeutic peptides. Our innovative approach enables the identification of peptidomimetic candidates interfering with the hetero- and/or the homodimerization of target receptors. PeptiMimesis will develop its pipeline against key targets in the fields of oncology, immuno-oncology and immune disease and is open to initiate collaboration with pharma partners on receptors of interest.

Opencell was created in 2015 to leverage an open source telco billing project initiated in 2007 by David Meyer, their current CEO. Their mission is to provide the first agile monetization platform capable of filling the gap between costly and complex legacy billing solutions and the overly simplistic “one size fits all” SaaS solutions that cover only the most basic requirements. Opencell is now the open source monetization and billing platform with over 40 successful implementations in multiple industries and countries.

Defymed is a worldwide leader in the development of innovative implantable medical devices that change the paradigm of therapeutics' administration. Defymed's innovations were developed to limit adverse events related to current standard of care based on site specific delivery of therapeutics. Our solutions aim for a precise administration of drugs, in a physiologic site, in order to improve disease's management and patients' quality of life. Up to date, two first in class technologies were developed by Defymed: MailPan®, a physiologic cell encapsulation device, and ExOlin®, a targeted drug delivery device (in clinics). Defymed owns an exclusive technology and know-how which positions its medical devices as a platform to meet several therapeutic applications, among which type 1 diabetes, hemophilia and cancer management. Defymed is certified ISO13485:2016. Defymed relies also on a strong and unique worldwide network gathering experts from the cell therapy and drug delivery fields. Defymed has been rewarded several times in Europe and in the USA, for its unique approaches to reinvent patients' journey.

Inoviem Scientific is a privately-owned contract research biotech (CRB) offering preclinical and clinical services that use cutting-edge proprietary technologies to speed up drug-development. Our pioneering technologies allow us to work in any therapeutic field and with any therapeutic compound (small chemical molecules, fragments, proteins, peptides, antibodies, etc). Our clients are any laboratories in the private or academic sphere working to develop therapeutic compounds. Our innovatory force lies with the technologies we have developed, and our strength generally resides in our ability to analyse drug-target interaction to a high degree of precision directly on crude human tissue, thus respecting physiological conditions. Our goal is to be your partner of choice for the development of drug candidates. Our technologies have the potential to bring to light information hidden within crude human tissue obtained from patients or healthy donors. Their use will significantly improve your chances of marketing your drug. As a technollogy and innovation driven CRB, Inoviem Scientific is continuously investing human and financial resources in the development of complementary technologies to bring the best technological, creative and innovative solutions to its clients. This continuous investment will reinforce our analysis power driving Inoviem Scientific to become: From preclinical to clinical: A leading explorer of drug-target interaction!

BioNext is a French biotechnology company dedicated to the better understanding and treatment of various diseases. BIONEXT aims to accelerate and improve the effectiveness of drug development and biological research by developping programs and software-based tools to tackle problematics of prime importance in the pharmaceutical field, such as drug profile assesment or suggestion of drug repurposing.